Xeris Biopharma Holdings Inc. (NASDAQ:XERS) saw an upside of 4.62% to $2.61 after adding $0.12 on Tuesday. The 5-day average trading volume is 755,726 shares of the company’s common stock. It has gained $2.78 in the past week and touched a new high 3 times within the past 5 days. An average of 849,962 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 1,087,109.
XERS’s 1-month performance is 6.33% or $0.22 on its low of $2.28 reached on 08/08/23. The company’s shares have touched a 52-week low of $0.97 and high of $3.07, with the stock’s rally to the 52-week high happening on 06/21/23. YTD, XERS has achieved 95.86% or $1.25 and has reached a new high 23 times. However, the current price is down -15.15% from the 52-week high price.
Valuation Metrics
XERS stock has a beta of 1.28. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 2.97 while the price-to-book (PB) in the most recent quarter is 11.84.
Xeris Biopharma Holdings Inc.’s quick ratio for the period ended March 30 was 1.70, with the current ratio over the same period at 2.00. As well, the company’s long term debt to equity for the quarter ending March 30 was 6.25, while the total debt to equity was 6.25. In terms of profitability, the gross margin trailing 12 months is 82.10%. The firm’s gross profit as reported stood at $87.61 million against revenue of $110.25 million.
Earnings Surprise
For the quarterly period ending March 30 this year, Xeris Biopharma Holdings Inc.’s cash and short-term investments amounted to $44.12 million against total debt of $198.42 million. Net income and sales went up compared to those figures reported in the previous quarter. Net income shrunk -292.81% to -$12.93 million, while revenue of -$21.83 million was -68.83% off the previous quarter. Analysts expected XERS to announce -$0.17 per share in earnings in its latest quarter, but it posted -$0.12, representing a 29.40% surprise. EBITDA for the quarter stood at more than -$10.2 million. XERS stock balance sheet for the quarter ending March 30 shows that total liabilities totaled 291.31 million, with total debt at $198.42 million. Shareholders hold equity totaling $137.31 million.
Let’s look briefly at Xeris Biopharma Holdings Inc. (XERS) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 07 August was 51.19% to suggest the stock is trending Neutral, with historical volatility in this time period at 70.52%.
The stock’s 5-day moving average is $2.59, reflecting a -4.10% or -$0.11 change from its current price. XERS is currently trading +6.60% above its 20-day SMA, +98.44% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by -9.17% and SMA200 by+109.73%.
Stochastic %K and %D was 59.37% and 65.96% and the average true range (ATR) pointed at 0.18. The RSI (14) points at 50.45%, while the 14-day stochastic is at 60.34% with the period’s ATR at 0.17. The stock’s 9-day MACD Oscillator is pointing at 0.00 and 0.03 on the 14-day charts.
Analyst Ratings
In the most recent analyst report for Xeris Biopharma Holdings Inc. (NASDAQ: XERS), Jefferies launched coverage with a Buy rating.
